Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citrafleet is a low-volume bowel preparation product used for cleansing the colon prior to elective colonoscopy or other diagnostic procedures. It is a combination of two active components: sodium picosulphate, a stimulant laxative that acts locally in the colon to increase peristalsis, and magnesium citrate (formed in solution from magnesium oxide and citric acid), which acts as an osmotic laxative by drawing water into the intestinal lumen. This dual mechanism promotes bowel evacuation. It was developed and is manufactured by Casen Recordati and has been evaluated in various clinical trials, including those comparing its efficacy and patient tolerability against polyethylene glycol (PEG)-based solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Citrafleet.